We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Cardiac Troponin Assays Compared in Large Cohort

By LabMedica International staff writers
Posted on 19 Nov 2018
Print article
Image: The automatic immunoassay analyzer / chemiluminescence ARCHITECT i1000SR (Photo courtesy of Abbott Diagnostics).
Image: The automatic immunoassay analyzer / chemiluminescence ARCHITECT i1000SR (Photo courtesy of Abbott Diagnostics).
High-sensitivity (hs) assays for the measurement of cardiac troponin T (cTnT) and cardiac troponin I (cTnI) are now used widely for the diagnosis of myocardial infarction. The universal definition of myocardial infarction recommends the 99th centile derived from a normal reference population be used to define myocardial necrosis.

However, it is also increasingly apparent that troponin concentrations well below this threshold provide diagnostic and prognostic information for patients with both acute and stable cardiovascular diseases and may have a role in screening the general population. Few studies have measured both cTnI and cTnT in a single large general population cohort.

A group of cardiology scientists mainly from the University of Glasgow (Glasgow, UK) measured troponins in serum from 19,501 individuals in the Generation Scotland Scottish Family Health Study. Associations with cardiovascular risk factors were compared using age- and sex-adjusted regression. Observed age- and sex-stratified 99th centiles were compared with 99th centiles for cTnT (men, 15.5 ng/L; women, 9.0 ng/L) and cTnI (men, 34.2 ng/L; women, 15.6 ng/L) used in clinical practice.

The team measured hs-cTnT and hs-cTnI on Cobas e411 and i1000SR analyzers, respectively. Both assays were calibrated and quality controlled using the manufacturer's reagents. Coefficients of variations (CVs) for cTnI were 6.2% for the low control, 6.0% for intermediate control, and 4.6% for high control. CVs for cTnT were 5.0% for the low control and 3.4% for the high control.

The team reported that cTnT and cTnI concentrations were detectable in 53.3% and 74.8% of participants, respectively, and were modestly correlated in unadjusted analyses (R2 = 21.3%) and only weakly correlated after adjusting for age and sex (R2 = 9.5%). Cardiovascular risk factors were associated with both troponins, but in age- and sex-adjusted analyses, cTnI was more strongly associated with age, male sex, body mass index, and systolic blood pressure. cTnT was more strongly associated with diabetes. The observed 99th centiles were broadly consistent with recommended 99th centiles in younger men and women. After the age of 60 years, observed 99th centiles increased substantially for cTnT, and beyond 70 years of age, the 99th centiles approximately doubled for both troponins.

The authors concluded in a large cohort study from a general population, cTnT and cTnI concentrations are differentially associated with cardiovascular risk factors and are weakly correlated with each other. Existing sex-specific 99th centiles are broadly appropriate for both men and women up to the age of 60 years. Beyond the age of 70 years, the 99th centile is approximately three-fold higher for cTnT in both men and women and two-fold higher for cTnI in women. The study was published in the October 2018 issue of the journal Clinical Chemistry.

Related Links:
University of Glasgow

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Total 25-Hydroxyvitamin D₂ & D₃ Assay
25-OH-VD Reagent Kit
New
Vaginitis Test
Allplex Vaginitis Screening Assay

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.